The FDA recorded a supplement on 8 October to Sandoz's abbreviated new drug application for tafluprost, the preservative-free prostaglandin analogue eye drop for glaucoma and ocular hypertension.
The notice gives no detail. Supplements to generic applications usually cover manufacturing, labelling or packaging changes, and this is not a new indication or a safety finding. Indian availability and any CDSCO position are not affected by this US action.
- Treat this as an administrative US generic supplement, not a change in tafluprost's evidence.
- Continue prescribing tafluprost on its existing indications.
- Consider preservative-free prostaglandins for patients with ocular surface disease.
Why it matters
It confirms continued generic supply of a preservative-free glaucoma drop in the US.
Don't overread it
A licence supplement is not a new indication or a safety signal.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free